The power of the Hoesch test
DOI:
https://doi.org/10.19230/jonnpr.2016.1.1.927Keywords:
Acute porphyria, porphyric crisis, Hoesch test, hemine, porphobilinogen.Abstract
Acute porphirias are a rare group of diseases in which the main clinical expression are abdominopsychoneurological crisis. The most typical symptom is abdominal pain.
If left untreated, acute porphyria attacks are associated with a high mortality rate (about 10%). Early diagnosis is very important. A rapid test to detect porphobilinogen (PBG) called the Hoesch test can be used for this purpose. If we have a positive test we can affirm that the clinical issues are induced by a porphyric attack. With this background, early treatment must be started with human hemin.
Our purpose is to prove the utility of the Hoesch test in the treatment period. Therefore, we made daily Hoesch tests in a porphyria crisis. We noticed that the Hoesch test remains positive without symptoms. It seems that the Hoesch test does not offer information to take the decision to stop treatment. More patients are necessary to prove this conclusion.
Downloads
References
Raili Kauppineu. Porphyrias. Lancet 2005; 365: 241-52.
R. Enriquez de Salamanca Lorente. Porfirias. Farreras-Rozman, Medicina Interna. Volumen 1. Capítulo 4,
páginas 22-29. 17ª edición. Barcelona: Elsevier, 2012.
Lamon JM, Fryklhom BC, Hess RA, Tschudy DP. Hematin therapy for acute porphyria. Medicine (Baltimore)
; 58 (3); 252-69.
No authors listed. Treatment of acute hepatic porphyria. Lancet 1978, Jun 24; 1 (8078): 1361-2.
Mustajki P, Nordmann Y. Early administration of heme argininato for acute porphyria attacks. Arch Internal Med
;13; 153 (17): 2004-8.
Walderburg M, Bonnot O, Mocellini R, Velakoulis D. The neuropsychiatrics of inborn errors of metabolism. J
Inherited Met Dis 2013; 36: 687-702.
Lamon J, With TK, Redeker AG. The Hoesch test: Bedside Screening for urinary porphobilinogen in patients with
suspected pophyria. Clin Chem 1979;20/11, 1438-1440.
A S Winkler, T J Peters, R D C Elwes. Neuropsychiatric porphyria in patients with refractory epilepsy: report of
three cases. J Neurol Neurosurg Psychiatry 2005;76:380–383.
Ylva Floderus, Eliane Sardh, Christer Möller, Claes Andersson, Lillan Rejkjaer, Dan E.H. Andersson et al.
Variations in Porphobilinogen and 5-Aminolevulinic Acid Concentrations in Plasma and Urine from Asymptomatic
Carriers of the Acute Intermittent Porphyria Gene with Increased Porphyrin Precursor Excretion. Clinical
Chemistry 2006;52:4 701–707.
F. Sedel, N. Baumann, J.-C. Turpin, O. Lyon-Caen, J.-M. Saudubray, D. Cohen. Psychiatric manifestations
revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis 2007; 30:631–641.
Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism
and the porphyrias. Metabolites. 2014;3:4(4):977-1006.
Downloads
Additional Files
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
